GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline
Shots:
- GSK has reported an agreement with Chimagen Biosciences to acquire the CMG1A46. GSK aims to develop & commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as SLE & LN, to expand into other related autoimmune disorders.
- As per the agreement, GSK will pay $300M upfront for full global rights to CMG1A46. Chimagen may also receive up to $550M in milestone payments based on the successful development & commercialization. The agreement is subject to standard conditions, including required regulatory approvals under the Hart-Scott-Rodino Act in the US.
- CMG1A46 is a dual-targeted TCE that focuses on CD19&20. It is currently in a P-I study for leukemia and lymphoma in the US & China. GSK intends to launch a P-I study for lupus in 2025.
Ref: GSK | Image: GSK & Chimagen
Related News:- GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
